Quality of life with palbociclib plus tamoxifen in hormone receptor-positive, HER2-negative advanced breast cancer: results from PATHWAY, an Asian international, double-blind, randomized phase 3 trial.
Takashi Yamanaka, Joohyuk Sohn, Kazuki Sudo et al.
✦ AI-curated · Sources linked
In 30 seconds
The PATHWAY trial evaluated the quality of life (QoL) in pre/peri or postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer receiving palbociclib plus tamoxifen versus placebo plus tamoxifen. This randomized controlled trial found no significant differences in QoL scores between treatment arms, but the palbociclib-tamoxifen group had a median time to deterioration in pain of 32.5 months compared to 21.2 months for the placebo group.
Key findings
- No significant differences in global QoL scores were observed between treatment arms at any assessment point.
- Median time to deterioration in pain was 32.5 months for palbociclib-tamoxifen versus 21.2 months for placebo-tamoxifen.
- The hazard ratio for time to deterioration in pain was 0.729, indicating a reduced risk for the palbociclib-tamoxifen group.
Why it matters
Understanding the impact of treatment on quality of life is crucial for managing advanced breast cancer. This study highlights that while QoL scores did not differ significantly, palbociclib-tamoxifen may offer a longer duration before pain deterioration, which is important for patient care.